<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003085</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000065784 (3P-94-1A)</org_study_id>
    <secondary_id>LAC-USC-3P941A</secondary_id>
    <secondary_id>NCI-V97-1339</secondary_id>
    <nct_id>NCT00003085</nct_id>
  </id_info>
  <brief_title>Laparoscopic Ultrasound in Diagnosing Patients With Pancreatic Cancer</brief_title>
  <official_title>Minimal Access Surgery for Pancreas Cancer: A Phase II Trial Study I: Staging of Pancreas Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: New diagnostic procedures, such as laparoscopic ultrasound, may improve the&#xD;
      ability to detect pancreatic cancer and determine the extent of disease.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of laparoscopic ultrasound in diagnosing&#xD;
      patients with stage I or stage II pancreatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine whether a comprehensive laparoscopic examination of the abdomen with&#xD;
      laparoscopic ultrasonography improves staging of pancreatic cancer with respect to (a) better&#xD;
      assessment (compared to CT) of the extent of localized extra pancreatic disease, (b) vascular&#xD;
      invasion, (c) regional lymph node involvement, and (d) metastatic deposits in liver&#xD;
      parenchyma. II. Assess whether one of the newer minimally invasive imaging techniques,&#xD;
      laparoscopic ultrasonography, predicts vascular invasion in pancreatic cancer. III. Develop&#xD;
      an optimal cost effective strategy for assessing resectability in pancreatic cancer.&#xD;
&#xD;
      OUTLINE: Patients who have undergone routine clinical staging (CT scan, angiogram, etc.) and&#xD;
      who have been classified as potentially resectable undergo laparoscopy and laparoscopic&#xD;
      ultrasound (L+LUS). At the end of the L+LUS, based on the new findings patients are&#xD;
      reclassified as either potentially resectable or potentially unresectable. All patient then&#xD;
      undergo definitive staging: those who have metastasis to the liver that can be pathologically&#xD;
      confirmed by biopsy at the time of the laparoscopy are classified as unresectable and do not&#xD;
      undergo laparotomy; all others undergo laparotomy and then are classified as resectable or&#xD;
      unresectable. If 8 or more patients are misclassified at the time of the L+LUS, then this&#xD;
      study is terminated.&#xD;
&#xD;
      PROJECTED ACCRUAL: There will be 50 patients accrued into this study with 25 patients in each&#xD;
      stage. In order to accrue 50 patients, approximately 70 patients will undergo the initial&#xD;
      routine clinical staging (CT scan, angiogram, etc.).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient Accrual&#xD;
  </why_stopped>
  <start_date>September 1996</start_date>
  <completion_date type="Actual">July 2000</completion_date>
  <primary_completion_date type="Actual">July 2000</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Diagnostic</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">28</enrollment>
  <condition>Pancreatic Cancer</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>laparoscopy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ultrasound imaging</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histological or radiological evidence of stage I or II pancreatic&#xD;
        cancer No evidence of metastatic disease on CT scan&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: Over 18 Performance status: ECOG 0-2 Life expectancy: Not&#xD;
        specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified&#xD;
        Cardiovascular: No prohibitive anesthetic risk due to cardiac disease Pulmonary: No&#xD;
        prohibitive anesthetic risk due to respiratory disease&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified&#xD;
        Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: No adhesions from&#xD;
        previous surgery that preclude laparoscopy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dilip Parekh, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033-0800</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>June 15, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2004</study_first_posted>
  <last_update_submitted>May 20, 2014</last_update_submitted>
  <last_update_submitted_qc>May 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I pancreatic cancer</keyword>
  <keyword>stage II pancreatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

